FirstWord Pharma’s Post

PERI has a great relationship with the US FDA and prominently features numerous experts in our Open Courses. Anyone involved in pharmaceutical development can attend and connect with these regulators! Listen and learn from FDA faculty at these upcoming courses (including Q&A panels!): ✅ Global Labeling & Regulatory Symposium (October 8-9) https://lnkd.in/gDmPtp4r ✅ Cancer: Pathophysiology, Current Therapies, Clinical Trials, and Drug Development (October 23-25) https://lnkd.in/gPhkNKMB ✅ Basic Drug Development: Overview of Biopharmaceutical Research & Development (November 20-22) https://lnkd.in/gVUwiK96 #drugdevelopment #cancer #oncology #labeling #regulatory #FDA

IRLAB Therapeutics AB In our recent analysis conducted with EQL desktop, we have reviewed IRLAB Therapeutics AB, a biopharmaceutical company based in Gothenburg, Sweden. Current Developments: IRLAB's development pipeline includes Mesdopetam in phase IIb/III trials for dyskinesia in Parkinson’s disease and several preclinical initiatives aimed at neurodegenerative disorders. Strategic Approach: Our research provides an objective look into IRLAB’s strategic methods and the progress of their clinical trials, presenting a clear picture of their operations and potential implications for patient care. Sign up today: https://lnkd.in/dJ8zhDrP #ResearchwithAI #EQL #Irlab #marketintelligence

Cyclolab attended the Congress of the Hungarian Society for Pharmaceutical Sciences and the EUFEPS Annual Meeting, which gathered pharmacists and researchers globally to discuss drug research, development, regulation, and therapeutic use. Dominika Herr, a research scientist from Cyclolab, presented a poster on the "Synthesis of folate-modified cyclodextrins as potential targeted drug-delivery systems." Her research focuses on developing targeted therapies for cancer cells using folate-modified SBECD, a cyclodextrin derivative to improve the specificity and efficacy of anti-cancer agents by exploiting the overexpression of folate receptors in various cancer types. #cyclolab #cyclodextrin #conference #meeting #drugresearch #drugdevelopment #SBECD #cancer #cancertherapy #pharma #pharmaceutical #pharmacist #pharmaindustry #science #chemistry #research

I had a great interview with Ken Keller, President and CEO of Daiichi Sankyo, at Financial Times' US Pharma and Biotech Summit today. He was one of the panelists discussing funding of #pharma and #biotech #innovation. Check it out!

Preclinical/discovery dominate licensing landscape (76%), followed by oncology being priority area (47%) and most excitingly small molecules are here to stay as the dominant modality (43%)!! Exciting times ahead for Avammune!!  Arun B Papaiah Srinivasan Namala

List of FDA Approved Biosimilars (2015-2023) Understanding Biosimilars https://lnkd.in/erQUfwi Approval Process for a Biosimilar https://lnkd.in/ebMEunu Biosimilars Explained https://lnkd.in/eU4jrtC8 Biosimilars and Biologics https://lnkd.in/eQj3Hfkd Biosimilars: Complex Copycat Drugs https://lnkd.in/emiy2Ynx Biosimilars: Are They the Same Quality? https://lnkd.in/e_yaY2Xz What is a Biosimilar? https://lnkd.in/eBi6Zn8 Biosimilar Development Process https://lnkd.in/eGDN65b Prescribing Biosinilar Products https://lnkd.in/exdgupp A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is approved based on a showing that it is highly similar to an already-approved biological product, known as a reference product. Biosimilars have no clinically meaningful differences from their reference product in terms of safety, purity and potency. https://lnkd.in/eVx_3DX https://lnkd.in/e29EUrC The biosimilar also must be shown to have no clinically meaningful differences in terms of safety and effectiveness from the reference product. Developed to offer patients additional treatment options, biosimilars are highly similar medications that show no clinically meaningful differences in terms of the safety, purity and potency between themselves and a licensed referenced biologic. They're designed to have a fingerprint like similarity to existing branded biologics. #Cancer #Oncology #biosimilar #biosimilars #BiosimilarProducts #Moffitt #MoffittCancerCenter Moffitt Cancer Center

📢 Press Release: Personalis, Inc. and ClearNote Health Announce Partnership to Advance Epigenomic Technology Personalis, a leader in advanced genomics for cancer, and ClearNote Health, a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform. Dave Mullarkey, CEO of ClearNote Health, remarked, “Partnering with Personalis presents an excellent opportunity to bring our 5hmC technology to the forefront of cancer research. This alliance is a testament to the synergy between our two companies, enabling us to expand our reach and significantly impact the biopharmaceutical industry. Together, we can accelerate the development of personalized therapies and make a real difference in the lives of patients.” 👉🏾 Read the full press release on our website: https://lnkd.in/d8H7t57H #epigenomics #personalizedmedicine

Certified for the participation in the 38th SPSR Webinar on 'SiRNAs: A New Era in Cancer Chemoprevention,' organized by the Society of Pharmaceutical Sciences and Research (SPSR) on the occasion of World Cancer Day, February 4, 2024. #awareness #worldcancerawarenessday #worldcancerday #SPSR #pharmacology #pharmaceuticals #pharmaindustry

I invite you to explore our new curated datasets crafted with direction by the Quest medical team and built utilizing our expansive screening, monitoring, prognostic, and diagnostic assays. These prebuilt, patient-deidentified datasets are drawn from over 313M unique patient encounters per year. Let me know if you would like to learn more!